Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report

Systemic treatment of psoriasis in special population

(2023) Shekhar Neema et al.   Indian Journal of Dermatology Venereology & Leprology

Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review

(2022) Yidong Zhao et al.   OncoTargets and Therapy

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment

(2022) Seong Keun Kim et al.   Frontiers in Pharmacology

Sintilimab for the treatment of non-small cell lung cancer

(2022) Lin Zhang et al.   Biomarker Research

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report

(2022) Gang Li et al.   Frontiers in Immunology

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice

(2022) Mònica Sabaté Gallego et al.   Frontiers in Medicine

Pembrolizumab-Induced Toxic Epidermal Necrolysis

(2022) Luca Borg et al.   Case Reports in Oncology

Oral mucositis—case series of a rare adverse effect associated with immunotherapy

(2021) Hardik Sheth et al.   SUPPORTIVE CARE IN CANCER

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients

(2021) Ritu Pandey et al.   Cancers

Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report

(2021) Jiashun Cao et al.   Translational Cancer Research

Adverse drug reactions in primary care: a scoping review

(2020) H. Khalil et al.   BMC HEALTH SERVICES RESEARCH

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

(2020) Paul Riviere et al.   MOLECULAR CANCER THERAPEUTICS

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

(2020) Lin Zhang et al.   Frontiers in Oncology

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Sintilimab: First Global Approval

(2019) Sheridan M. Hoy   DRUGS

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

(2019) Jie Wang et al.   mAbs

Drug–drug–gene interactions and adverse drug reactions

(2019) Mustafa Adnan Malki et al.   PHARMACOGENOMICS JOURNAL

Effect Of Coexisting Kras And Tp53 Mutations In Patients Treated With Chemotherapy For Non-Small Cell Lung Cancer

(2018) Pascale Tomasini et al.   Clinical Lung Cancer

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

(2018) Liang Zeng et al.   OncoTargets and Therapy

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer

(2017) Gen Lin et al.   Oncotarget

Adverse drug reactions

(2016) J. J. Coleman et al.   CLINICAL MEDICINE

Ocular and orbital side-effects of checkpoint inhibitors

(2016) Joëlle Antoun et al.   CURRENT OPINION IN ONCOLOGY

Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: An Indian perspective

(2016) LalitKumar Gupta et al.   Indian Journal of Dermatology Venereology & Leprology

Classifying ADRs - does dose matter?

(2015) Elizabeth J. Phillips   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial

(2015) Reason Wilken et al.   Trials

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): Could Retinoids Play a Causative Role?

(2015) Sridhar Karre   MEDICAL SCIENCE MONITOR

Life-threatening dermatologic adverse events in oncology

(2013) Alyx C. Rosen et al.   ANTI-CANCER DRUGS

Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma

(2013) Takashi Ishida et al.   CANCER SCIENCE

Factors affecting the development of adverse drug reactions (Review article)

(2013) Muaed Jamal Alomar   SAUDI PHARMACEUTICAL JOURNAL